SJS Investment Consulting Inc. Acquires 76 Shares of Johnson & Johnson (NYSE:JNJ)

SJS Investment Consulting Inc. raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,094 shares of the company’s stock after acquiring an additional 76 shares during the period. SJS Investment Consulting Inc.’s holdings in Johnson & Johnson were worth $513,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Lantz Financial LLC grew its position in Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock valued at $1,986,000 after acquiring an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. bought a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $453,000. Horan Securities Inc. grew its holdings in shares of Johnson & Johnson by 1.3% in the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after purchasing an additional 90 shares during the last quarter. Strategic Financial Concepts LLC grew its holdings in shares of Johnson & Johnson by 57.9% in the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after purchasing an additional 1,271 shares during the last quarter. Finally, State of Wyoming grew its holdings in shares of Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company’s stock worth $1,487,000 after purchasing an additional 10,279 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

JNJ has been the topic of several recent analyst reports. Barclays cut their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a report on Thursday, April 17th. Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Wall Street Zen lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Finally, Bank of America dropped their price target on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, April 10th. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Price Performance

JNJ opened at $156.45 on Wednesday. The stock has a 50-day moving average price of $153.52 and a 200-day moving average price of $153.69. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a market cap of $376.43 billion, a PE ratio of 23.53, a P/E/G ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.32%. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is currently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.